Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
Status:
Not yet recruiting
Trial end date:
2026-09-01
Target enrollment:
Participant gender:
Summary
This is a first in human study in patients with advanced or metastatic solid tumors known to
have an MTAP deletion. The first part of the study is an open-label, dose escalation and the
second part is an open label dose expansion in specific MTAP-deleted tumor types. The study
drug, TNG462, is a selective PRMT5 inhibitor administered orally. The study is planned to
treat up to 159 participants.